{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:13:38Z","timestamp":1767168818382,"version":"build-2238731810"},"reference-count":20,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Evidence-Based Complementary and Alternative Medicine"],"published-print":{"date-parts":[[2022,8,9]]},"abstract":"<jats:p>\n                    Purpose. To investigate the clinical value of interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 10 (IL-10), tumor necrosis factor \u03b1 (TNF-\u03b1), and interferon-\u03b3 (IFN-\u03b3) in diagnosis and severity assessment of lung cancer. Methods. In this observational study, 50 physical examination healthy subjects were included in the control group and 100 lung cancer patients were included in the study group. In the study group, 53 cases with pleural effusion were subgrouped to the pleural effusion group (n\u2009=\u200953), while 47 patients were assigned to the nonpleural effusion group (n\u2009=\u200947). Plasma cytokines IL-2, IL-4, IL-6, IL-10, TNF-\u03b1, IFN-\u03b3, and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores of all eligible subjects were collected and compared. Results. The study group showed significantly higher levels of plasma cytokines IL-2, IL-4, IL-6, IL-10, TNF-\u03b1, and IFN-\u03b3 versus healthy subjects (\n                    <jats:inline-formula>\n                      <a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\">\n                        <a:mi>P<\/a:mi>\n                        <a:mo>&lt;<\/a:mo>\n                        <a:mn>0.05<\/a:mn>\n                      <\/a:math>\n                    <\/jats:inline-formula>\n                    ). Deterioration of lung cancer was associated with increased plasma cytokine levels and APACHE II scores. The combination assay of the above plasma cytokines showed significantly better diagnostic efficacy for lung cancer versus the single assay of the cytokines. Dead patients had higher plasma cytokine levels versus survived patients. The accuracy of plasma IL-2, IL-4, IL-6, IL-10, TNF-\u03b1, and IFN-\u03b3 levels in the severity assessment of lung cancer was comparable with that of the APACHE II scale. Conclusion. The plasma cytokines IL-2, IL-4, IL-6, IL-10, TNF-\u03b1, and IFN-\u03b3 are effective markers for the diagnosis of lung cancer. The combined assay contributes to the early diagnosis of lung cancer patients, and the persistent elevation of cytokines suggests an increased risk of death in lung cancer patients, so the detection of cytokine levels facilitates the severity assessment of lung cancer.\n                  <\/jats:p>","DOI":"10.1155\/2022\/4641600","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T18:20:15Z","timestamp":1660069215000},"page":"1-5","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Value of Cytokine Assay in Diagnosis and Severity Assessment of Lung Cancer"],"prefix":"10.1155","volume":"2022","author":[{"given":"Jin","family":"Ma","sequence":"first","affiliation":[{"name":"Laboratory, The Third Hospital of Hebei Medical University, Shijiazhuang 050051, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4436-9224","authenticated-orcid":true,"given":"Shumin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang 050030, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zining","family":"Liu","sequence":"additional","affiliation":[{"name":"Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang 050030, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafei","family":"Mao","sequence":"additional","affiliation":[{"name":"Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang 050030, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyuan","family":"Li","sequence":"additional","affiliation":[{"name":"Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang 050030, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Dai","sequence":"additional","affiliation":[{"name":"Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang 050030, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojie","family":"Zhao","sequence":"additional","affiliation":[{"name":"Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang 050030, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congzhen","family":"Wei","sequence":"additional","affiliation":[{"name":"Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang 050030, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinfeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang 050030, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7230-6004","authenticated-orcid":true,"given":"Yulan","family":"Geng","sequence":"additional","affiliation":[{"name":"Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang 050030, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"issue":"10","key":"1","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1080\/15384047.2018.1456599","article-title":"Breast cancer lung metastasis: molecular biology and therapeutic implications","volume":"19","author":"L. Jin","year":"2018","journal-title":"Cancer Biology & Therapy"},{"key":"2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canlet.2020.03.016","article-title":"Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma","volume":"479","author":"C. Zhang","year":"2020","journal-title":"Cancer Letters"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8040543"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01515-6"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.01.125"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13085"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e06155"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.628456"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201948336"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000405"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0662-0"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190418"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.3109\/08923973.2013.863912"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1038\/srep05595"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1080\/14789450.2021.1892491"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0399-6"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1177\/1533033820951807"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.607881"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kww159"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00157"}],"updated-by":[{"DOI":"10.1155\/2023\/9812186","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"record-id":"45815"},{"DOI":"10.1155\/2023\/9812186","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000}}],"container-title":["Evidence-Based Complementary and Alternative Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/ecam\/2022\/4641600.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ecam\/2022\/4641600.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ecam\/2022\/4641600.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T18:20:22Z","timestamp":1660069222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/ecam\/2022\/4641600\/"}},"subtitle":[],"editor":[{"given":"Zhaoqi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":20,"alternative-id":["4641600","4641600"],"URL":"https:\/\/doi.org\/10.1155\/2022\/4641600","relation":{},"ISSN":["1741-4288","1741-427X"],"issn-type":[{"value":"1741-4288","type":"electronic"},{"value":"1741-427X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,9]]}}}